Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02987387 · ClinicalTrials.gov registry record
COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction
A clinical trial, sponsored by Edwards Lifesciences.
- Completed
- Registry status
- 57
- Enrollment target
NCT02987387: Completed study, sponsored by Edwards Lifesciences.
NCT02987387 is a clinical trial that has completed, run by Edwards Lifesciences. The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02987387 has completed, sponsored by Edwards Lifesciences.
- COMPLETED
- Registry status
- 57 participants
- Enrollment target
Study Summary
This study will confirm the safety and effectiveness of the Edwards Lifesciences SAPIEN XT Transcatheter Heart Valve (THV) System in patients with a dysfunctional right ventricular outflow tract (RVOT) conduit with a clinical indication for intervention in a post-market setting.
Interventions
- DEVICE SAPIEN XT THV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2025-09-30 |
What the finished NCT02987387 record still lists
NCT02987387 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 57 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SAPIEN XT THV is the first listed.
NCT02987387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02987387 about?
NCT02987387 is a clinical study titled "COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction". This study will confirm the safety and effectiveness of the Edwards Lifesciences SAPIEN XT Transcatheter Heart Valve (THV) System in patients with a dysfunctional right ventricular outflow tract (RVOT) conduit with a clinical indication for intervention in a post-market setting.
What is the current status of trial NCT02987387?
This trial is currently completed. The enrollment target is 57 participants. The study started on 2017-07-17. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT02987387?
The interventions under investigation include: SAPIEN XT THV (DEVICE).
Who is sponsoring clinical trial NCT02987387?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI